Southlake, TX – January 4, 2023 – OncoNano Medicine, Inc. today announced three poster presentations at…
Read More
Southlake, TX – January 4, 2023 – OncoNano Medicine, Inc. today announced that its lead clinical…
Clinically validated pH-sensitive nanomedicine platform allows for tumor specific delivery of protein therapeutics and increased…
ONM-501 shown to be promising immuno-therapeutic candidate for clinical evaluation in solid tumors SOUTHLAKE, Texas…
– Interim Phase 2 results presented at World Molecular Imaging Conference 2022 – – Pegsitacianine…
SOUTHLAKE, Texas – September 19, 2022 – OncoNano Medicine, Inc., a clinical-stage biotechnology company focused…
SOUTHLAKE, Texas – September 14, 2022 – OncoNano Medicine, Inc. today announced a presentation of…
– Oncology Development Veteran to Lead the Advancement of OncoNano’s Portfolio SOUTHLAKE, Texas – June…
SOUTHLAKE, Texas – May 10, 2022 – OncoNano Medicine, Inc. today announced the appointment of…
– ONM-501 is a dual-activating polyvalent STING agonist for immuno-oncology applications formulated with OMNI™, the…